Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Next Previous
X
Search
Trial Profile

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hemay 022 (Primary) ; Exemestane; Fulvestrant; Letrozole
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions
  • Sponsors Tianjin Hemay Pharmaceutical Sci-Tech

    • Most Recent Events

    • 09 Dec 2023 Status changed from recruiting to completed.
    • 09 Dec 2023 Results assessing Antitumor efficacy and safety of sacibertinib in combination with endocrine therapy,presented at the 46th Annual San Antonio Breast Cancer Symposium
    • 27 Apr 2021 Planned End Date changed from 7 Jul 2021 to 7 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top